Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402918 | 0.87 | EGFR (0.43) | EGFRERBB2SRCFGFR1FLT1 | |
| Trifluoroacetic Acid SCHEMBL4032839 | 0.82 | EGFR (0.58) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL6429537 | 0.79 | EGFR (0.47) | EGFRERBB2SRCFGFR1FLT1 | |
| SCHEMBL6407667 | 0.76 | EGFR (0.42) | EGFRSRCKDR | |
| SCHEMBL6405839 | 0.75 | EGFR (0.49) | EGFRERBB2SRCKDR | |
| Trifluoroacetic Acid SCHEMBL4033517 | 0.75 | EGFR (0.70) | EGFRERBB2SRCKCNH2 | |
| Trifluoroacetic Acid SCHEMBL4039319 | 0.75 | EGFR (0.53) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL5475801 | 0.74 | EGFR (0.54) | EGFRERBB2SRCHTR2CHTR2B | |
| SCHEMBL6403835 | 0.74 | SRC (0.54) | EGFRERBB2SRCFGFR1FLT1 | |
| Trifluoroacetic Acid SCHEMBL4034846 | 0.74 | EGFR (0.52) | EGFRERBB2SRCKDRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885SRC 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.